Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

IMPULSE IMProving User experience, Long-term sustainability and Services of EU-OPENSCREEN

Coordinator
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric), Germany
Runs
1 March 2024 to 28 February 2027
Status
Running
EU funding
€4.0m
Total cost
€5.0m
Partners
25 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101132028

What the project is doing

In the project's own words, from its summary on CORDIS.

EU-OPENSCREEN (EU-OS), the distributed European Research Infrastructure for Chemical Biology and early drug discovery, provides world-class services in high-throughput compound screening and medicinal chemistry to users from academia and industry. As one of the largest open-access initiative globally, EU-OPENSCREEN plays an increasingly important role in facilitating early stage drug discovery in Europe. It recently integrated fragment-based drug discovery and chemoproteomics as two new services, but the increasing complexity of modern drug discovery projects requires an even more comprehensive portfolio and integration of emerging technologies.

To ensure that EU-OS continues to offer a comprehensive suite of relevant services and support a growing user community to conduct forefront research, IMPULSE will develop, validate and integrate new services in AI/ML, new chemical modalities, and innovative disease-relevant cell models combined with CRISPR-Cas9/RNAi-based genetic screening. IMPULSE will work towards the implementation of common operational and data standards to increase data reproducibility and FAIRness.

Bespoke outreach and training activities will raise awareness among key user groups of its new services and advance operational excellence and reproducibility in pre-clinical drug discovery. New models for pre-competitive drug discovery with industry or charities, and growing ERIC member community will reinforce the sustainability and accessibility of EU-OPENSCREEN.

Topics

Who is involved

OrganisationCityCountryRole
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric)BerlinGermanyCoordinator
Masarykova univerzitaBrnoCzechiaParticipant
Univerzita Palackeho V OlomouciOlomoucCzechiaParticipant
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaParticipant
Forschungsverbund Berlin eVBerlinGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Helmholtz-Zentrum Fur Infektionsforschung GmbHBraunschweigGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Fundacion Centro De Excelencia En Investigacion De Medicamentos Innovadores En AndaluciaArmilla GranadaSpainParticipant
Fundacion De La Comunidad Valenciana Centro De Investigacion Principe FelipeValenciaSpainParticipant
Universidad De Santiago De CompostelaSantiago De CompostelaSpainParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Turun YliopistoTurkuFinlandParticipant
Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts""""RigaLatviaParticipant
Universitetet I BergenBergenNorwayParticipant
Universitetet I OsloOsloNorwayParticipant
Instytut Biochemii I Biofizyki Polskiej Akademii NaukWarszawaPolandParticipant
Instytut Biologii Medycznej Polskiej Akademii NaukLodzPolandParticipant
Instytut Chemii Bioorganicznej Polskiej Akademii NaukPoznanPolandParticipant
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Universidade Do PortoPortoPortugalParticipant
Karolinska InstitutetStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI